Skopos Labs, Inc. Alkermes Plc. Transaction History
Skopos Labs, Inc.
- $330 Million
- Q4 2024
A detailed history of Skopos Labs, Inc. transactions in Alkermes Plc. stock. As of the latest transaction made, Skopos Labs, Inc. holds 90 shares of ALKS stock, worth $2,652. This represents 0.0% of its overall portfolio holdings.
Number of Shares
90
Previous 36
150.0%
Holding current value
$2,652
Previous $1,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ALKS
# of Institutions
361Shares Held
181MCall Options Held
175KPut Options Held
96.6K-
Black Rock Inc. New York, NY29.1MShares$858 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$559 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD13MShares$383 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA12.7MShares$373 Million0.06% of portfolio
-
State Street Corp Boston, MA9.19MShares$271 Million0.01% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.84B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...